Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Pinnacle Research Group

Neither a doctor nor a teaching hospital

Research payments

$5,080,273

239 payments

Through program year 2025, Pinnacle Research Group is reported as receiving $5,080,273 in research payments, across 239 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $229,104 19
2024 Research $806,769 14
2023 Research $2,312,101 67
2022 Research $713,555 6
2021 Research $374,516 26
2020 Research $268,631 33
2019 Research $375,597 74

Breakdown

Who paid Research payments · program years 2019–2025
  1. AstraZeneca UK Limited $1,516,179 4 payments
  2. Horizon Therapeutics plc $1,025,035 2 payments
  3. AstraZeneca Pharmaceuticals LP $832,555 6 payments
  4. Novo Nordisk AS $521,866 88 payments
  5. Novartis Pharmaceuticals Corporation $408,641 11 payments
  6. GlaxoSmithKline, LLC. $253,084 24 payments
  7. Amgen Inc. $193,784 5 payments
  8. Kowa Research Institute, Inc. $92,990 6 payments
  9. Ironwood Pharmaceuticals, Inc $81,942 19 payments
  10. Chugai Pharmaceutical Co., Ltd. $68,106 5 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase I,Randomized,Safety and Pharmacokinetics Study of AZD3152 in Healthy Adults Little DIPPER $1,496,586 2 payments
  2. A Phase 1, Open-Label, Single Center Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of A Single Dose of Dazodalibep in Healthy Japanese and Caucasian Participants $814,661 1 payment
  3. Phase 1, Randomized, Open label, Three-arm, Single Dose, Parallel Group Study to Compare AZD7442 (AZD8895 and AZD1061) Pharmacokinetic Exposure Following Intramuscular Administration as a Co-formulation versus Administration from Two Separate Vials of the Individual Monoclonal Antibodies in Adult Healthy Participants $738,791 3 payments
  4. Nn9536-4373 $386,675 36 payments
  5. A Randomized, Double-blind, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) $229,892 2 payments
  6. A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of 0178Vib1116 0178In Conventional Dendritic Cell (CDC) and Plasmacytoid Dendritic Cell (PDC) Mediat $210,374 1 payment
  7. AMG 407 (OTEZLA) - Ph 3 COVID Consortium Study $193,347 3 payments
  8. A Phase 4, Multicenter, Prospective, Open-Label Study Describing the E $165,635 12 payments
  9. Nn9536-4376 $103,406 34 payments
  10. A Phase I/II Observer-Blind, Randomized, Multi-Center Trial to Evaluat $85,273 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record